Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Other Accumulated Expenses (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Other Accumulated Expenses for 2 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 37.2% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 37.2% year-over-year, with the annual reading at $4.0 million for FY2025, 37.2% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $4.0 million at Pyxis Oncology, down from $6.4 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $6.4 million in Q4 2024, with the low at $4.0 million in Q4 2025.